04.05.2021 • NewsHexion

Hexion Completes Phenolic Resins Sale

Hexion has completed the sale of its phenolic specialty resin, hexamine and European-based forest products resins businesses to private equity investors Investindustrial and Black Diamond Capital Management for about $425 million. The deal, which took effect after all approvals, was announced in September 2020.

Columbus, Ohio, USA-based Hexion, which supplies the global adhesive, coatings, composites and industrial markets, said it plans to use the proceeds to invest in its business and further reduce debt. CEO Craig Rogerson added that the sale strengthens the company’s balance sheet while maintaining a strong specialty chemical portfolio going forward.

Investindustrial is a European group of independently managed investment, holding and advisory companies with €11 billion of raised fund capital. Black Diamond based in Stamford, Connecticut, focuses on underwriting, trading, restructuring and managing stressed, distressed and private equity investments. Funds managed by the two investors own equal shares in Polynt-Reichhold, formed in 2017 from the merger between Italy’s Polynt and US-based Reichhold.

Author: Dede Williams, Freelance Journalist

Hexion has completed the sale of its phenolic specialty resin, hexamine and...
Hexion has completed the sale of its phenolic specialty resin, hexamine and European-based forest products resins businesses to private equity investors Investindustrial and Black Diamond Capital Management for $425 million. Proceeds will be reinvested and used to reduce debt. (c) Hexion

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.